Registered title, quoted from ClinicalTrials.gov
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07645222, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Received at least 1 line SoC,or treatment naïve;
Inclusion criterion 2
Local radiotherapy within 2 weeks prior to first dose of investigational drug
Exclusion criterion 2
Major surgery within 4 weeks prior to first dose of investigational drug
Exclusion criterion 4
Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
Exclusion criterion 6
History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
Exclusion criterion 15
Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
Inclusion criterion 5
With at least 1 target lesion according to RECIST 1.1.
Inclusion criterion 3
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07645222, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Locally advanced or metastastic NSCLC;
- Received at least 1 line SoC,or treatment naïve;
- With at least 1 target lesion according to RECIST 1.1.
- Appropriate organ function
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
- Minimum expected survival longer than 12 weeks
- Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.
- Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.
Exclusion Criteria:
- Insufficient wash out duration of prior systemic anticancer therapy
- Local radiotherapy within 2 weeks prior to first dose of investigational drug
- Pleural/abdominal effusion requires clinical intervention
- Major surgery within 4 weeks prior to first dose of investigational drug
- History of drugs may prolong QT interval
- Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
- Presence of brain metastasis or carcinomatous meningtitis
- History of other primary malignancies
- Significant, uncontrolled, or active cardiovascular diseases
- Severe or poorly controlled diabetes
- Extremely obesity or emaciation
- Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose
- Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose
- Severe infection within 4 weeks
- History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
- Presence of known active infectious diseases,
- Prensence of ophthalmological abnormalities.
17.Presence of hepatic encephalopathy, Hepato-renal Syndrome 18.Presence or history of confirmed or suspected ILD; 19.Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.
20.History of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.
21.Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.
Quoted from ClinicalTrials.gov, NCT07645222, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07645222, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.